Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

Abstract

Background Although real-life results of sofosbuvir/simeprevir have been extensively reported from the United States, data from other geographical areas are limited. In the French observational cohort, ANRS CO22 HEPATHER, 9432 patients were given the new oral antivirals from December 2013 to June 30, 2018. We report the results of sofosbuvir/simeprevir in genotypes 1- and 4-infected patients. Methods Demographics and history of liver disease were collected at entry in the cohort. Clinical, adverse events, and virological data were collected throughout treatment and post-treatment follow-up. The choice of treatment duration or addition of ribavirin was left up to the physician. Results Five hundred ninety-nine HCV (467 genotype 1 and 132 genotype 4) mono-infected, naïve for all oral-DAAs regimen patients were given sofosbuvir/simeprevir with ( n = 63) or without ribavirin ( n = 536) for 12 or 24 weeks; 56% had cirrhosis (4% decompensated) and 71% had prior treatment failure to interferon-based regimen. 7 patients (1.16%) were lost to follow-up. The overall SVR12 rate was 92.6%. The SVR12 was 90% in GT1a, 94.2% in GT1b and 91.6% in GT4 with no significant difference for genotype, treatment duration or ribavirin addition. Severity of liver disease was not associated with a lower SVR12 rate on multivariate analysis but was associated with a higher rate of severe side effects. Early treatment discontinuations were rare; no new safety signals were reported. Conclusion In this real life, observational, prospective cohort study, the 12-week sofosbuvir/simeprevir+/−ribavirin combination appears to be efficient and safe. Trial registration Trial registration with ClinicalTrials.gov NCT01953458 .

Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia

“…The recent development of highly effective directly acting antiviral therapy (DAAs) has dramatically changed the treatment of HCV and reduced morbidity and mortality [3]. In real-world treatment using DAA-based regimens, sustained virologic response (SVR) rates of > 90% have been reported [4][5][6]. In light of this, the World Health Organisation's has developed a global strategy that aims to eliminate HCV by 2030.…”

Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?

“…This safer second and third generation PIs were followed by daclatasvir and sofosbuvir ( 5 ) (Figure ) used as NS5A and NS5B polymerase inhibitors, respectively. In particular, treatment of naı̈ve patients with sofosbuvir ( 5 ) in combination with peg-IFN and ribavirin allowed to achieve an SVR rate of 90% after only 12 weeks. , These drugs showed to be effective against gt1 subclasses (gt1a and gt1b). However, some patients affected by gt2 and gt3 achieved a high SVR rate after dual therapy of sofosbuvir ( 5 ) and ribavirin .…”

Viral hepatitis C treatment shortening – what is the limit?

“…However, for RBV intolerant patients extension to 24 weeks was recommended [12, 14]. Effectiveness of SOF + SMV combination administered according to this protocol reached over 90% [15]. Unfortunately, an attempt to apply SOF + SMV for 8 weeks resulted in a significant SVR rate reduction, so shortening of this treatment below 12 weeks was never recommended [16].…”